2008
DOI: 10.1002/hep.22791
|View full text |Cite
|
Sign up to set email alerts
|

Locating the stem cell niche and tracing hepatocyte lineages in human liver

Abstract: We have used immunohistochemical and histochemical techniques to identify patches of hepatocytes deficient in the enzyme cytochrome c oxidase, a component of the electron transport chain and encoded by mitochondrial DNA (mtDNA). These patches invariably abutted the portal tracts and expanded laterally as they spread toward the hepatic veins. Here we investigate, using mtDNA mutations as a marker of clonal expansion, the clonality of these patches. Negative hepatocytes were laser-capture microdissected and muta… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
102
0

Year Published

2009
2009
2022
2022

Publication Types

Select...
6
2

Relationship

2
6

Authors

Journals

citations
Cited by 137 publications
(104 citation statements)
references
References 28 publications
2
102
0
Order By: Relevance
“…Alison and colleagues have harnessed the inability of the cell to repair mutations in mitochondrial DNA to ask whether human livers have such progenitors (8,45). By identifying cells in which the mitochondria have a COX mutation, this group described patches of epithelium in the liver in which the mitochondria were mutated, and when random, discrete regions of the patch were analyzed the mitochondrial mutation was consistent across the sample.…”
Section: Figurementioning
confidence: 99%
See 1 more Smart Citation
“…Alison and colleagues have harnessed the inability of the cell to repair mutations in mitochondrial DNA to ask whether human livers have such progenitors (8,45). By identifying cells in which the mitochondria have a COX mutation, this group described patches of epithelium in the liver in which the mitochondria were mutated, and when random, discrete regions of the patch were analyzed the mitochondrial mutation was consistent across the sample.…”
Section: Figurementioning
confidence: 99%
“…In many liver diseases, such as chronic viral hepatitis (5) and non-alcoholic fatty liver disease (6), hepatocytes become senescent and unable to efficiently regenerate the parenchyma. In this scenario, hepatic progenitor cells (HPCs) become activated and are sufficient to regenerate the biliary and hepatocellular epithelium (7,8). The biology of HPCs is less studied in comparison to analogous progenitor cells in other adult tissues, and markers that delineate the stem versus transit amplifying populations are not clearly defined (9)(10)(11).…”
Section: Introductionmentioning
confidence: 99%
“…showed how, in aged individuals, there is an increased number of single randomly distributed myocytes and cardiomyocytes without Cytochrome c oxidase (COX) activity [93,94]. COX-deficient succinate dehydrogenase (SDH)-positive single neurons with high mtDNA deletions increase in aged-linked neurodegenerative diseases such as Alzheimer's and Parkinson's disease [95][96][97]; moreover, focal respiratory chain defects accumulate to significant levels in aging human colon [59], liver, pancreas [98], stomach [99], and small intestine [92]. Through clonal expansion, both de novo and inherited mutations would increase with age ( Figure 1).…”
Section: The Clonal Expansion Theorymentioning
confidence: 99%
“…Also, patches of hepatocytes deficient in cytochrome c oxidase activity contain clonal mtDNA mutations, suggesting their origin from a stem cell [98].…”
Section: From Mtdna Damage To Tissue Failurementioning
confidence: 99%
“…[4][5][6][7][8][9][10][11][12] With the recent focus on embryonic SCs (ESCs) and induced pluripotent SCs (iPSCs), interest into in vitro generation of HSCs, including signals for HSC expansion and differentiation from these more primitive SCs, has seen a tremendous boost. [13][14][15] As HSC-based therapy is the only type of SC therapy routinely used, much knowledge obtained from the clinical application of HSCs and from genetic modification of HSCs for gene therapy applications can be used to introduce other types of adult SC therapies, and perhaps in the future extend this to include ESCs and iPSCs.…”
Section: Introductionmentioning
confidence: 99%